Gynäkologie und Geburtshilfe

Forschung und Studien

Therapieoptimierungsstudien Mammakarzinom: SUCCES, TEACH, PACT, IBIS II, IPK211, CLEOS

Publikationen Prof. Dr. Wolfgang Simon

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007 Nov 20;25(33):5187-93. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M, Brauch H.

Symptom-oriented follow-up of early breast cancer is not inferior to conventional control. Results of a prospective multicentre study. Onkologie. 2007 Sep;30(8-9):443-9. Epub 2007 Sep 7.  Bornhak S, Heidemann E, Herschlein HJ, Simon W, Merkle E, Widmaier G, Ernst R, Greulich M, Bittner R, Kieninger G, Merkle P, Strosche H, Karg C, Wellhaeusser U, Aulitzky W, Schmidt B, Metzger H, Hahn M, Stauch A, Meisner C, Selbmann HK, Regelmann C, Brinkmann F.

Growth/adhesion-regulatory tissue lectin galectin-3: stromal presence but not cytoplasmic/nuclear expression in tumor cells as a negative prognostic factor in breast cancer. Anticancer Res. 2007 Jul-Aug;27(4B):2131-9. Moisa A, Fritz P, Eck A, Wehner HD, Mürdter T, Simon W, Gabius HJ.

Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer. Pharmacogenet Genomics. 2007 Jul;17(7):529-38, Jaremko M, Justenhoven C, Schroth W, Abraham BK, Fritz P, Vollmert C, Illig T, Simon W, Schwab M, Brauch H.